Pacira BioSciences Urges Shareholder Support in Proxy Battle, Highlights Strong Performance & $200M Buyback

summarizeSummary

Pacira BioSciences filed definitive additional proxy materials, urging shareholders to vote for its nominees in the ongoing proxy contest and detailing its strong operational progress, significant share repurchases, and refreshed board.

check_boxKey Events

• Proxy Contest Intensifies

  Pacira filed definitive additional proxy materials, urging shareholders to vote for its nominees and against DOMA Perpetual's candidates in the upcoming June 9th Annual Meeting.

• Strong Operational Performance Highlighted

  The company highlighted successful execution of its "5x30 strategy," reporting a 35% stock increase since its launch, record gross margins, and advancements in its product pipeline and partnerships.

• Significant Share Repurchases

  Pacira detailed returning $200 million to stockholders through share repurchases since 2025, reducing outstanding common shares from 47 million to 39 million.

• New Board Nominee Introduced

  Thomas Wiggans, a seasoned biopharmaceutical executive with over 40 years of leadership experience, was nominated to the board.

auto_awesomeAnalysis

This DEFA14A provides Pacira BioSciences' full letter to shareholders, intensifying its defense against activist investor DOMA Perpetual ahead of the June 9th Annual Meeting. The company strongly advocates for its three board nominees, including new nominee Thomas Wiggans, while criticizing DOMA's candidates as underqualified. The filing highlights the successful execution of Pacira's "5x30 strategy," which has seen the stock rise over 35% and delivered record gross margins. Crucially, Pacira emphasizes its commitment to shareholder returns, detailing $200 million in share repurchases since 2025, which significantly reduced outstanding shares. This communication aims to solidify investor confidence in the current management and strategic direction amidst the contested board election.